Clinical Trial Update: AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating AMD3100 with busulfan, fludarabine, and thymoglobulin for allogeneic stem cell transplantation in acute myeloid leukemia and myelod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AMD3100 (plerixafor) (plerixafor)
• BUSULFAN (Busulfan)
• Fludarabine (Fludara) (fludarabine)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: WITHDRAWN